CME Wants Option To Limit OTC Clearing
CME Group’s ceo, Craig Donohue, said he wants his firm to have the option to decline clearing certain OTC derivatives.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ 4 capital markets databases
- ✔ Daily newsletters across markets and asset classes
- ✔ 2 weekly podcasts
